{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:33:00Z","timestamp":1779409980554,"version":"3.53.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02720-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:03:07Z","timestamp":1779408187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fulvestrant versus capecitabine as maintenance therapy in hormone receptor-positive, HER2-negative metastatic breast cancer after first-line chemotherapy (FAMILY): a multicenter, open-label, randomized, phase 3 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Wenjing","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinduo","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5923-3306","authenticated-orcid":false,"given":"Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijian","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quchang","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxiaoxiao","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziliang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyu","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengcai","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-5780","authenticated-orcid":false,"given":"Shusen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-6220","authenticated-orcid":false,"given":"Yunfang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2720_CR1","first-page":"480","volume":"73","author":"LA Huppert","year":"2023","unstructured":"Huppert, L. A., Gumusay, O., Idossa, D. & Rugo, H. S. Systemic therapy for hormone receptor-positive\/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. CA Cancer J. Clin. 73, 480\u2013515 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"2720_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso, F. et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann. Oncol. 31, 1623\u20131649 (2020).","journal-title":"Ann. Oncol."},{"key":"2720_CR3","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.breast.2021.12.017","volume":"61","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. Real world initial palliative treatment patterns and clinical outcomes in premenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a study of the National Cancer Center, China. Breast 61, 129\u2013135 (2022).","journal-title":"Breast"},{"key":"2720_CR4","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/CM9.0000000000002676","volume":"136","author":"Y Yuan","year":"2023","unstructured":"Yuan, Y. et al. Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer. Chin. Med. J. 136, 1459\u20131467 (2023).","journal-title":"Chin. Med. J."},{"key":"2720_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/annonc\/mdv544","volume":"27","author":"DJ Lobbezoo","year":"2016","unstructured":"Lobbezoo, D. J. et al. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann. Oncol. 27, 256\u2013262 (2016).","journal-title":"Ann. Oncol."},{"key":"2720_CR6","doi-asserted-by":"publisher","first-page":"103866","DOI":"10.1016\/j.critrevonc.2022.103866","volume":"180","author":"C Vieira","year":"2022","unstructured":"Vieira, C., Piperis, M. N., Sagkriotis, A. & Cottu, P. Systemic treatment for hormone receptor-positive\/HER2-negative advanced\/metastatic breast cancer: a review of European real-world evidence studies. Crit. Rev. Oncol. Hematol. 180, 103866 (2022).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2720_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103691","volume":"9","author":"SM Tolaney","year":"2024","unstructured":"Tolaney, S. M. et al. Real-world treatment patterns and outcomes in patients with HR+\/HER2- metastatic breast cancer treated with chemotherapy in the United States. ESMO Open 9, 103691 (2024).","journal-title":"ESMO Open"},{"key":"2720_CR8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.03.013","volume":"95","author":"E Jacquet","year":"2018","unstructured":"Jacquet, E. et al. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients. Eur. J. Cancer 95, 93\u2013101 (2018).","journal-title":"Eur. J. Cancer"},{"key":"2720_CR9","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ejca.2019.06.014","volume":"118","author":"O Le Saux","year":"2019","unstructured":"Le Saux, O. et al. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur. J. Cancer 118, 131\u2013141 (2019).","journal-title":"Eur. J. Cancer"},{"key":"2720_CR10","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1200\/JCO.24.00144","volume":"42","author":"YS Lu","year":"2024","unstructured":"Lu, Y. S. et al. Final results of RIGHT choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer. J. Clin. Oncol. 42, 2812\u20132821 (2024).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR11","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1016\/j.annonc.2020.08.423","volume":"31","author":"K Lewis","year":"2020","unstructured":"Lewis, K. et al. 321P First-line treatment patterns in HR+\/HER2- locally advanced or metastatic breast cancer in Europe. Ann. Oncol. 31, S371\u2013S372 (2020).","journal-title":"Ann. Oncol."},{"key":"2720_CR12","doi-asserted-by":"publisher","first-page":"S375","DOI":"10.1016\/j.annonc.2020.08.429","volume":"31","author":"K Lewis","year":"2020","unstructured":"Lewis, K. et al. 327P Treatment sequencing in HR+\/HER2- locally advanced or metastatic breast cancer: a real-world retrospective study in France, Germany, Italy and Spain. Ann. Oncol. 31, S375\u2013S376 (2020).","journal-title":"Ann. Oncol."},{"key":"2720_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.breast.2020.08.011","volume":"54","author":"A Schneeweiss","year":"2020","unstructured":"Schneeweiss, A. et al. Initial experience with CDK4\/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer-data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 54, 88\u201395 (2020).","journal-title":"Breast"},{"key":"2720_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100573","volume":"26","author":"M Meegdes","year":"2023","unstructured":"Meegdes, M. et al. Real-world time trends in overall survival, treatments and patient characteristics in HR+\/HER2- metastatic breast cancer: an observational study of the SONABRE Registry. Lancet Reg. Health Eur. 26, 100573 (2023).","journal-title":"Lancet Reg. Health Eur."},{"key":"2720_CR15","doi-asserted-by":"crossref","unstructured":"Breast Cancer Expert Committee of National Quality Control Center for, C., Breast Cancer Expert Committee of China Anti-Cancer, A. & Cancer Drug Clinical Research Committee of China Anti-Cancer, A Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition). J. Natl. Cancer Cent. 4, 107\u2013127 (2024).","DOI":"10.1016\/j.jncc.2023.12.001"},{"key":"2720_CR16","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1056\/NEJM199111073251904","volume":"325","author":"HB Muss","year":"1991","unstructured":"Muss, H. B. et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. Piedmont Oncol. Assoc. N. Engl. J. Med 325, 1342\u20131348 (1991).","journal-title":"Piedmont Oncol. Assoc. N. Engl. J. Med"},{"key":"2720_CR17","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1200\/JCO.2012.45.2490","volume":"31","author":"YH Park","year":"2013","unstructured":"Park, Y. H. et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J. Clin. Oncol. 31, 1732\u20131739 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR18","first-page":"614","volume":"39","author":"MA Nooij","year":"2003","unstructured":"Nooij, M. A. et al. Continuing chemotherapy or not after the induction treatment in advanced breast cancer patients. Clin. Outcomes Oncologists\u2019 Preferences Eur. J. Cancer 39, 614\u2013621 (2003).","journal-title":"Clin. Outcomes Oncologists\u2019 Preferences Eur. J. Cancer"},{"key":"2720_CR19","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","volume":"29","author":"A Gennari","year":"2011","unstructured":"Gennari, A. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J. Clin. Oncol. 29, 2144\u20132149 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10549-010-0860-9","volume":"122","author":"E Alba","year":"2010","unstructured":"Alba, E. et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study. Breast Cancer Res. Treat. 122, 169\u2013176 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"2720_CR21","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1200\/JCO.2006.06.1812","volume":"24","author":"A Gennari","year":"2006","unstructured":"Gennari, A. et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J. Clin. Oncol. 24, 3912\u20133918 (2006).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR22","first-page":"692","volume":"26","author":"H Lv","year":"2014","unstructured":"Lv, H. et al. Efficacy of capecitabine-based combination therapy and single-agent capecitabine maintenance therapy in patients with metastatic breast cancer. Chin. J. Cancer Res. 26, 692\u2013697 (2014).","journal-title":"Chin. J. Cancer Res."},{"key":"2720_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0533-y","volume":"32","author":"M Segura-Gonzalez","year":"2015","unstructured":"Segura-Gonzalez, M. & Quintana-Quintana, M. Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute. Med. Oncol. 32, 93 (2015).","journal-title":"Med. Oncol."},{"key":"2720_CR24","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","volume":"15","author":"J Gligorov","year":"2014","unstructured":"Gligorov, J. et al. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 15, 1351\u20131360 (2014).","journal-title":"Lancet Oncol."},{"key":"2720_CR25","first-page":"550","volume":"26","author":"X Liang","year":"2014","unstructured":"Liang, X. et al. Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. Chin. J. Cancer Res. 26, 550\u2013557 (2014).","journal-title":"Chin. J. Cancer Res."},{"key":"2720_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1023\/A:1006169012544","volume":"55","author":"O Kloke","year":"1999","unstructured":"Kloke, O. et al. Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy: results of a randomized trial. Ess. Breast Cancer Study Group Breast Cancer Res. Treat. 55, 51\u201359 (1999).","journal-title":"Ess. Breast Cancer Study Group Breast Cancer Res. Treat."},{"key":"2720_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.7150\/ijms.5.100","volume":"5","author":"A Dufresne","year":"2008","unstructured":"Dufresne, A. et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int. J. Med Sci. 5, 100\u2013105 (2008).","journal-title":"Int. J. Med Sci."},{"key":"2720_CR28","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.breast.2013.08.013","volume":"22","author":"S Lim","year":"2013","unstructured":"Lim, S. et al. Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer. Breast 22, 1205\u20131209 (2013).","journal-title":"Breast"},{"key":"2720_CR29","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1200\/JCO.2008.21.1136","volume":"27","author":"JF Robertson","year":"2009","unstructured":"Robertson, J. F. et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J. Clin. Oncol. 27, 4530\u20134535 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR30","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.1016\/S0140-6736(16)32389-3","volume":"388","author":"JFR Robertson","year":"2016","unstructured":"Robertson, J. F. R. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 388, 2997\u20133005 (2016).","journal-title":"Lancet"},{"key":"2720_CR31","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1200\/JCO.2015.61.5831","volume":"33","author":"MJ Ellis","year":"2015","unstructured":"Ellis, M. J. et al. Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: overall survival analysis from the phase II FIRST study. J. Clin. Oncol. 33, 3781\u20133787 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR32","doi-asserted-by":"publisher","first-page":"e742","DOI":"10.1002\/onco.13614","volume":"26","author":"F Xu","year":"2021","unstructured":"Xu, F. et al. A pPhase II study of fulvestrant 500 mg as maintenance therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative patients with advanced breast cancer after first-line chemotherapy. Oncologist 26, e742\u2013e748 (2021).","journal-title":"Oncologist"},{"key":"2720_CR33","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.4143\/crt.2021.698","volume":"54","author":"W Ren","year":"2022","unstructured":"Ren, W. et al. Clinical evidence of chemotherapy or endocrine therapy maintenance in patients with metastatic breast cancer: meta-analysis of randomized clinical trials and propensity score matching of multicenter cohort study. Cancer Res. Treat. 54, 1038\u20131052 (2022).","journal-title":"Cancer Res. Treat."},{"key":"2720_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s40265-017-0855-5","volume":"78","author":"ED Deeks","year":"2018","unstructured":"Deeks, E. D. Fulvestrant: a review in advanced breast cancer not previously treated with endocrine therapy. Drugs 78, 131\u2013137 (2018).","journal-title":"Drugs"},{"key":"2720_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1001\/jama.2020.23370","volume":"325","author":"X Wang","year":"2021","unstructured":"Wang, X. et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: the SYSUCC-001 randomized clinical trial. JAMA 325, 50\u201358 (2021).","journal-title":"JAMA"},{"key":"2720_CR36","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda, N. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376, 2147\u20132159 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2720_CR37","first-page":"345","volume":"32","author":"TL King","year":"2024","unstructured":"King, T. L., Voon, P. J., Yuen, K. H. & Mohamed Noor, D. A. Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia. Support Care Cancer 32, 345 (2024).","journal-title":"Support Care Cancer"},{"key":"2720_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-084290","volume":"390","author":"Y Xia","year":"2025","unstructured":"Xia, Y. et al. Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial. BMJ 390, e084290 (2025).","journal-title":"BMJ"},{"key":"2720_CR39","doi-asserted-by":"publisher","first-page":"100443","DOI":"10.1016\/j.clinme.2025.100443","volume":"25","author":"S Banerjee","year":"2025","unstructured":"Banerjee, S. & Sengupta, S. Population-specific DPYD variants and fluoropyrimidine toxicity risk: an analysis using public genomic databases. Clin. Med. 25, 100443 (2025).","journal-title":"Clin. Med."},{"key":"2720_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.08.007","volume":"72","author":"T Decker","year":"2023","unstructured":"Decker, T. et al. Anti-hormonal maintenance treatment with the CDK4\/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive\/HER2 negative metastatic breast cancer: A phase II trial (AMICA). Breast 72, 103575 (2023).","journal-title":"Breast"},{"key":"2720_CR41","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"2720_CR42","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465\u20132472 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR43","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr.","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR44","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904\u20131909 (2021).","journal-title":"Nat. Med."},{"key":"2720_CR45","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1200\/JCO.2009.25.6529","volume":"28","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American Society of Clinical Oncology\/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784\u20132795 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2720_CR46","unstructured":"X Wang, et al. Efficacy and safety of capecitabine monotherapy versus other maintenance regimenes-a multicentre CSCO series of advanced breast cancer maintenance studies. Chinese Clinical Oncology, Special Issue of 2014 CSCO Annual Meeting (Abstract No. CI012) (2014)."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02720-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02720-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:03:11Z","timestamp":1779408191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02720-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2720"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02720-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"191"}}